Bbva Compass Bancshares Inc. Invests $226,000 in Balchem Co. (BCPC)

Bbva Compass Bancshares Inc. purchased a new position in Balchem Co. (NASDAQ:BCPC) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 2,015 shares of the basic materials company’s stock, valued at approximately $226,000.

Other large investors have also added to or reduced their stakes in the company. Zeke Capital Advisors LLC acquired a new position in shares of Balchem in the second quarter worth about $203,000. Cubist Systematic Strategies LLC acquired a new position in shares of Balchem in the second quarter worth about $218,000. Granahan Investment Management Inc. MA acquired a new position in shares of Balchem in the second quarter worth about $224,000. Sigma Planning Corp acquired a new position in shares of Balchem in the second quarter worth about $229,000. Finally, CIBC Asset Management Inc acquired a new position in shares of Balchem in the second quarter worth about $240,000. Institutional investors and hedge funds own 88.48% of the company’s stock.

Shares of Balchem stock opened at $90.12 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.42 and a quick ratio of 2.82. The stock has a market capitalization of $2.94 billion, a P/E ratio of 35.62 and a beta of 0.97. Balchem Co. has a fifty-two week low of $70.23 and a fifty-two week high of $117.79.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Tuesday, November 6th. The basic materials company reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.12. The firm had revenue of $155.04 million during the quarter, compared to analyst estimates of $163.66 million. Balchem had a return on equity of 14.51% and a net margin of 15.67%. Balchem’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 earnings per share. Equities research analysts anticipate that Balchem Co. will post 2.45 earnings per share for the current fiscal year.

Several brokerages recently weighed in on BCPC. HC Wainwright began coverage on Balchem in a report on Tuesday, September 25th. They issued a “buy” rating for the company. BidaskClub lowered Balchem from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 29th. ValuEngine raised Balchem from a “hold” rating to a “buy” rating in a report on Thursday, August 30th. Finally, Sidoti raised Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price objective for the company in a report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. Balchem has a consensus rating of “Hold” and a consensus target price of $122.33.

TRADEMARK VIOLATION WARNING: This report was first posted by WKRB News and is the property of of WKRB News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.wkrb13.com/2018/11/10/bbva-compass-bancshares-inc-invests-226000-in-balchem-co-bcpc.html.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Recommended Story: Compound Interest and Why It Matters When Investing

Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).

Institutional Ownership by Quarter for Balchem (NASDAQ:BCPC)

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply